Evidence Hub

Analgesia in Tactical Combat Casualty Care (TCCC): TCCC Guideline Change 25-03

Barbee GA, Byrne BT, Clayton CE, Cole JH, Conklin CC, Donovan KA, Fisher AD, Gelfand HJ et al.

Journal of special operations medicine : a peer reviewed journal for SOF medical professionals, 2026

Abstract

Battlefield pain management (BPM) is a critical and ethical component of TCCC. In 2025, the loss of access to oral trans-mucosal fentanyl citrate (OTFC) and a strategic focus on large-scale combat operations prompted the Committee on Tactical Combat Casualty Care (CoTCCC) to update its analgesia guidelines. The CoTCCC performed an extensive literature review to address key questions regarding OTFC alternatives, ketamine dosing, ethical challenges, and scalability. The review identified buprenorphine and intranasal esketamine as viable alternatives to OTFC, based on their pharmacology, efficacy, and safety. The updated TCCC guidelines propose a simpli-fied, two-step model: Step 1 recommends a non-opioid pill pack for mission-capable casualties, including a novel sodium channel inhibitor, suzetrigine; and Step 2 advises a fixed dose of ketamine (or esketamine) via intramuscular, intranasal, or slow intravenous/intraosseous push alongside the pill pack for non-mission-capable casualties. This framework reduces provider cognitive burden, simplifies logistics, and enhances battlefield analgesia. Recommendations are rated from level of evidence A to C-EO and Class I to IIa, highlighting future research needs.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free